Plakous Therapeutics

Plakous Therapeutics developed a patented platform biotherapeutic to prevent the rare pediatric disease, necrotizing enterocolitis, and a follow-on indication for osteoarthritis. It has generated compelling preclinical data for both conditions, but the unmet medical need and the regulatory efficiencies of NEC as a rare pediatric disease have led the company to prioritize the NEC development effort. It received rare pediatric disease and orphan drug designations from the FDA, and is currently raising $20M to complete IND-enabling studies and enter clinical trials.